NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $0.27 +0.01 (+3.85%) (As of 11/6/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About NKGen Biotech Stock (NYSE:NKGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NKGen Biotech alerts:Sign Up Key Stats Today's Range$0.25▼$0.2850-Day Range$0.23▼$0.8752-Week Range$0.20▼$4.06Volume549,074 shsAverage Volume2.86 million shsMarket Capitalization$9.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address NKGN Stock News HeadlinesNKGen Flat on Presentation of Alzheimer's TreatmentOctober 30, 2024 | baystreet.caNKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 29, 2024 | globenewswire.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonNovember 7, 2024 | Porter & Company (Ad)NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)October 15, 2024 | globenewswire.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 8, 2024 | finance.yahoo.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 8, 2024 | globenewswire.comNKGen Biotech (NASDAQ:NKGN) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comNKGen Biotech (NASDAQ:NKGN) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comSee More Headlines NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $2.75 at the beginning of the year. Since then, NKGN stock has decreased by 90.2% and is now trading at $0.27. View the best growth stocks for 2024 here. How were NKGen Biotech's earnings last quarter? NKGen Biotech, Inc. (NYSE:NKGN) posted its earnings results on Thursday, September, 12th. The company reported ($0.67) EPS for the quarter. Who are NKGen Biotech's major shareholders? Top institutional investors of NKGen Biotech include Sequoia Financial Advisors LLC (0.27%). Insiders that own company stock include Paul Y Song and James A Graf. View institutional ownership trends. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NKGen Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI). Company Calendar Last Earnings9/12/2024Today11/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CUSIPN/A CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-479.36% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual Sales$80,000.00 Price / Sales119.34 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.10Miscellaneous Outstanding Shares35,360,000Free Float8,964,000Market Cap$9.55 million OptionableNot Optionable Beta0.53 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NYSE:NKGN) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.